Outline of Salivary Gland Pathogenesis of Sjögren's Syndrome and Current Therapeutic Approaches.

Int J Mol Sci · 2023 · PMC10342367 · PMID 37446355

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A phase 2 randomized, double-blind, placebo-controlled proof-of-concept trial of seletalisib, a potent and selective PI3Kδ inhibitor, in pSS showed a trend toward improvement in ESSDAI and ESSPRI at week 12.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.